Anne Hulin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anne Hulin has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
- Abdel Aissat
Département de Génétique et Biologie Moléculaire, DMU Biologie Pathologie, Assistance Publique Hôpitaux de Paris-APHP, Hôpital Henri Mondor, 94000 Créteil, France
2 shared publications - Aline Rifflet
Biologie et Génétique de la Paroi Bactérienne, UMR/Inserm U1306, Institut Pasteur, 75000 Paris, France
2 shared publications - Benoit Rousseau
Memorial Sloan Kettering Cancer Center, New York, NY, USA
2 shared publications - Bijan Ghaleh
Inserm, U955, Equipe 03, F-94000 Créteil, France
2 shared publications - Christophe Junot
Département Médicaments et Technologies pour la Santé (DMTS), MetaboHUB, CEA, INRAE, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
2 shared publications Christophe Tournigand
Department of Medical Oncology, Henri Mondor Hospital, APHP, Creteil, France; GERCOR, Paris, France
2 shared publications
Latest Publications
- Open Access
- 22 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 26
Potential Impact of Microbial Dysbiosis and Tryptophan Metabolites in Advanced Stages of Colorectal Cancer
Background/Objectives: We conducted an untargeted metabolomic study in serum, urine, and fecal water in colorectal cancer (CRC) patients compared to healthy controls. The aim was to define the interactions between metabolites and microbiota. Methods: Effluents were collected before colonoscopy. Metabolites were analyzed using LC-HRMS. Bioinformatics analyses included Limma test, along with spectral house and public databases for annotations. Whole-genome shotgun sequencing was performed on fecal samples. Species–metabolite interactions were calculated using Spearman correlation. Interleukins and inflammatory proteins were measured. Results: Fifty-three patients (11 stage I, 10 stage II, 10 stage III, and 22 stage IV) and twenty controls were included. Derivatives of deoxycholic acid, cholic acid, and fatty acids were lower in serum, while urinary bile acids were higher in stage IV CRC patients (versus controls). Metabolites related to tryptophan and glutamate were found significantly altered in stage IV: upregulation of kynurenine and downregulation of indole pathways. This was linked to increased inflammatory protein and microbial metabolites and to the imbalance between virulent pro-inflammatory bacteria (Escherichia and Desulfovibrio) and symbiotic (Ruminococcus and Bifidobacterium) bacteria. Conclusions: E. coli-related tryptophan catabolism shift is shown through stage IV CRC as compared to controls. As a consequence, tryptophan/kynurenine metabolite may become a promising marker for detecting the failure to immune response during therapy.
- 22 December 2025
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 26
Open AccessPotential Impact of Microbial Dysbiosis and Tryptophan Metabolites in Advanced Stages of Colorectal Cancer
Background/Objectives: We conducted an untargeted metabolomic study in serum, urine, and fecal water in colorectal cancer (CRC) patients compared to healthy controls. The aim was to define the interactions between metabolites and microbiota. Methods: Effluents were collected before colonoscopy. Metabolites were analyzed using LC-HRMS. Bioinformatics analyses included Limma test, along with spectral house and public databases for annotations. Whole-genome shotgun sequencing was performed on fecal samples. Species–metabolite interactions were calculated using Spearman correlation. Interleukins and inflammatory proteins were measured. Results: Fifty-three patients (11 stage I, 10 stage II, 10 stage III, and 22 stage IV) and twenty controls were included. Derivatives of deoxycholic acid, cholic acid, and fatty acids were lower in serum, while urinary bile acids were higher in stage IV CRC patients (versus controls). Metabolites related to tryptophan and glutamate were found significantly altered in stage IV: upregulation of kynurenine and downregulation of indole pathways. This was linked to increased inflammatory protein and microbial metabolites and to the imbalance between virulent pro-inflammatory bacteria (Escherichia and Desulfovibrio) and symbiotic (Ruminococcus and Bifidobacterium) bacteria. Conclusions: E. coli-related tryptophan catabolism shift is shown through stage IV CRC as compared to controls. As a consequence, tryptophan/kynurenine metabolite may become a promising marker for detecting the failure to immune response during therapy.
- Open Access
- 12 November 2025
- Published by MDPI AG in Preprints.org
Impact of Microbial Dysbiosis and Tryptophan Metabolites in Advanced Stages of Colorectal Cancer
Background/Objectives: We conducted an untargeted metabolomic study in serum, urine and fecal water in colorectal cancer (CRC) patients compared to healthy controls. The aim was to define the interactions between metabolites and microbiota. Methods: Ef-fluents were collected before colonoscopy. Metabolites were analyzed using LC-HRMS. Bioinformatics analyses included Limma test, along with spectral house and public da-tabases for annotations. Whole-genome shotgun sequencing was performed on fecal sam-ples. Species-metabolite interactions were calculated using Spearman correlation. Inter-leukins and inflammatory proteins were measured. Results: Fifty-three patients (11 stage-I, 10 stage-II, 10 stage-III and 22 stage-IV) and twenty controls were included. Derivatives of deoxycholic acid, cholic acid and fatty acids were lower in serum while urinary bile acids were higher in stage-IV CRC patients (versus controls). Metabolites related to tryptophan and glutamate were found significantly altered in stage-IV: upregulation of Kynurenine and downregulation of indole pathways. This was linked to increased inflammatory pro-tein and microbial metabolites and to the imbalance between virulent pro-inflammatory bacteria (Escherichia, Desulfovibrio) and symbiotic (Ruminococcus, Bifidobacterium) bacteria. Conclusions: E. coli-related Tryptophan catabolism shift is shown through stage-IV CRC as compared to controls. As a consequence, Tryptophan/kynurenine metabolite may become a promising marker for detecting the failure to immune response during therapy.
- 12 November 2025
- Published by MDPI AG in Preprints.org
Open AccessImpact of Microbial Dysbiosis and Tryptophan Metabolites in Advanced Stages of Colorectal Cancer
Background/Objectives: We conducted an untargeted metabolomic study in serum, urine and fecal water in colorectal cancer (CRC) patients compared to healthy controls. The aim was to define the interactions between metabolites and microbiota. Methods: Ef-fluents were collected before colonoscopy. Metabolites were analyzed using LC-HRMS. Bioinformatics analyses included Limma test, along with spectral house and public da-tabases for annotations. Whole-genome shotgun sequencing was performed on fecal sam-ples. Species-metabolite interactions were calculated using Spearman correlation. Inter-leukins and inflammatory proteins were measured. Results: Fifty-three patients (11 stage-I, 10 stage-II, 10 stage-III and 22 stage-IV) and twenty controls were included. Derivatives of deoxycholic acid, cholic acid and fatty acids were lower in serum while urinary bile acids were higher in stage-IV CRC patients (versus controls). Metabolites related to tryptophan and glutamate were found significantly altered in stage-IV: upregulation of Kynurenine and downregulation of indole pathways. This was linked to increased inflammatory pro-tein and microbial metabolites and to the imbalance between virulent pro-inflammatory bacteria (Escherichia, Desulfovibrio) and symbiotic (Ruminococcus, Bifidobacterium) bacteria. Conclusions: E. coli-related Tryptophan catabolism shift is shown through stage-IV CRC as compared to controls. As a consequence, Tryptophan/kynurenine metabolite may become a promising marker for detecting the failure to immune response during therapy.
- Open Access
- 5 July 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (8) , 1997-2006
Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study
Introduction Caspofungin pharmacokinetics may be altered in critically ill patients. In vitro studies suggest significant drug adsorption with polyacrylonitrile (PAN) membranes during continuous renal replacement therapy (CRRT). Methods This study retrospectively analyzed 66 plasma caspofungin concentrations (pCASconc) from 35 ICU patients between 2021 and 2024, comparing those on PAN-CRRT (n = 19) versus those without (n = 47). Results Caspofungin is mainly prescribed for candidemia (40%) and invasive Candida infections (25.7%). Median pCASconc at 12 h was similar between groups, but at 18 and 24 h, it was significantly higher in the PAN-CRRT group [5.3 (4.1–6.9) vs. 3.3 (1.9–3.7) mg/L, p = 0.04 and 5.3 (3.9–5.8) vs. 3.1 (2.5–4.5) mg/L, p = 0.01, respectively]. ECMO use was more frequent in PAN-CRRT patients (75% vs. 21.7%, p = 0.01). Persistent candidemia occurred in three patients (one in PAN-CRRT, two in non-PAN-CRRT). Conclusion This study found no evidence of caspofungin depletion with PAN-CRRT, warranting further research on clinical outcomes.
- 5 July 2025
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 14 (8) , 1997-2006
Open AccessImpact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study
Introduction Caspofungin pharmacokinetics may be altered in critically ill patients. In vitro studies suggest significant drug adsorption with polyacrylonitrile (PAN) membranes during continuous renal replacement therapy (CRRT). Methods This study retrospectively analyzed 66 plasma caspofungin concentrations (pCASconc) from 35 ICU patients between 2021 and 2024, comparing those on PAN-CRRT (n = 19) versus those without (n = 47). Results Caspofungin is mainly prescribed for candidemia (40%) and invasive Candida infections (25.7%). Median pCASconc at 12 h was similar between groups, but at 18 and 24 h, it was significantly higher in the PAN-CRRT group [5.3 (4.1–6.9) vs. 3.3 (1.9–3.7) mg/L, p = 0.04 and 5.3 (3.9–5.8) vs. 3.1 (2.5–4.5) mg/L, p = 0.01, respectively]. ECMO use was more frequent in PAN-CRRT patients (75% vs. 21.7%, p = 0.01). Persistent candidemia occurred in three patients (one in PAN-CRRT, two in non-PAN-CRRT). Conclusion This study found no evidence of caspofungin depletion with PAN-CRRT, warranting further research on clinical outcomes.
- 11 December 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (7) , 927-938
Pharmacology of Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins. Often reliant on efflux and influx transporters, TKI undergo primary metabolism by intestinal and hepatic cytochrome P450 enzymes, with nonkidney clearance being predominant. Owing to their limited therapeutic window, many TKI display considerable intraindividual and interindividual variability. This review offers a comprehensive analysis of the clinical pharmacokinetics of TKI, detailing their interactions with drug transporters and metabolic enzymes, while discussing potential clinical implications. The prevalence of kidney conditions, such as AKI and CKD, among patients with cancer is explored in their effect on TKI pharmacokinetics. Finally, the potential nephrotoxicity associated with TKI is also examined.
- 11 December 2023
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (7) , 927-938
Pharmacology of Tyrosine Kinase Inhibitors
Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins. Often reliant on efflux and influx transporters, TKI undergo primary metabolism by intestinal and hepatic cytochrome P450 enzymes, with nonkidney clearance being predominant. Owing to their limited therapeutic window, many TKI display considerable intraindividual and interindividual variability. This review offers a comprehensive analysis of the clinical pharmacokinetics of TKI, detailing their interactions with drug transporters and metabolic enzymes, while discussing potential clinical implications. The prevalence of kidney conditions, such as AKI and CKD, among patients with cancer is explored in their effect on TKI pharmacokinetics. Finally, the potential nephrotoxicity associated with TKI is also examined.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e230567
Glomerular Filtration Rate Measured Based on Iomeprol Clearance Assessed at CT Urography in Living Kidney Donor Candidates
Background Estimating glomerular filtration rate (GFR) from serum creatinine can be inaccurate, and current procedures for measuring GFR are time-consuming and cumbersome. Purpose To develop a method for measuring GFR based on iomeprol clearance assessed at CT urography in kidney donor candidates and compare this with iohexol clearance (reference standard for measuring GFR). Materials and Methods This cross-sectional retrospective study included data from kidney donor candidates who underwent both iohexol clearance and CT urography between July 2016 and October 2022. CT-measured GFR was calculated as the iomeprol excretion rate in the urinary system between arterial and excretory phases (Hounsfield units times milliliters per minute) divided by a surrogate for serum iomeprol concentration in the aorta at the midpoint (in Hounsfield units). Performance of CT-measured GFR was assessed with use of mean bias (mean difference between CT-measured GFR and iohexol clearance), precision (the distance between quartile 1 and quartile 3 of the bias [quartile 3 minus quartile 1], with a small value indicating high precision), and accuracy (percentage of CT-measured GFR values falling within 10%, 20%, and 30% of iohexol clearance values). Intraobserver agreement was assessed for 30 randomly selected individuals with the Lin concordance correlation coefficient. Results A total of 75 kidney donor candidates were included (mean age, 51 years ± 13 [SD]; 45 female). The CT-measured GFR was unbiased (1.1 mL/min/1.73 m2 [95% CI: -1.9, 4.1]) and highly precise (16.2 mL/min/1.73 m2 [quartiles 1 to 3, -6.6 to 9.6]). The accuracy of CT-measured GFR within 10%, 20%, and 30% was 61.3% (95% CI: 50.3, 72.4), 88.0% (95% CI: 80.7, 95.4), and 100%, respectively. Concordance between CT-based GFR measurements taken 2 months apart was almost perfect (correlation coefficient, 0.99 [95% CI: 0.98, 0.99]). Conclusion In living kidney donors, GFR measured based on iomeprol clearance assessed at CT urography showed good agreement with GFR measured based on iohexol clearance. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Davenport in this issue.
- 1 December 2023
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 309 (3) , e230567
Glomerular Filtration Rate Measured Based on Iomeprol Clearance Assessed at CT Urography in Living Kidney Donor Candidates
Background Estimating glomerular filtration rate (GFR) from serum creatinine can be inaccurate, and current procedures for measuring GFR are time-consuming and cumbersome. Purpose To develop a method for measuring GFR based on iomeprol clearance assessed at CT urography in kidney donor candidates and compare this with iohexol clearance (reference standard for measuring GFR). Materials and Methods This cross-sectional retrospective study included data from kidney donor candidates who underwent both iohexol clearance and CT urography between July 2016 and October 2022. CT-measured GFR was calculated as the iomeprol excretion rate in the urinary system between arterial and excretory phases (Hounsfield units times milliliters per minute) divided by a surrogate for serum iomeprol concentration in the aorta at the midpoint (in Hounsfield units). Performance of CT-measured GFR was assessed with use of mean bias (mean difference between CT-measured GFR and iohexol clearance), precision (the distance between quartile 1 and quartile 3 of the bias [quartile 3 minus quartile 1], with a small value indicating high precision), and accuracy (percentage of CT-measured GFR values falling within 10%, 20%, and 30% of iohexol clearance values). Intraobserver agreement was assessed for 30 randomly selected individuals with the Lin concordance correlation coefficient. Results A total of 75 kidney donor candidates were included (mean age, 51 years ± 13 [SD]; 45 female). The CT-measured GFR was unbiased (1.1 mL/min/1.73 m2 [95% CI: -1.9, 4.1]) and highly precise (16.2 mL/min/1.73 m2 [quartiles 1 to 3, -6.6 to 9.6]). The accuracy of CT-measured GFR within 10%, 20%, and 30% was 61.3% (95% CI: 50.3, 72.4), 88.0% (95% CI: 80.7, 95.4), and 100%, respectively. Concordance between CT-based GFR measurements taken 2 months apart was almost perfect (correlation coefficient, 0.99 [95% CI: 0.98, 0.99]). Conclusion In living kidney donors, GFR measured based on iomeprol clearance assessed at CT urography showed good agreement with GFR measured based on iohexol clearance. © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Davenport in this issue.
- 27 May 2022
- Published by Elsevier in Infectious Diseases Now
- Vol. 52 (5) , 273-279
Probenecid, an old β-lactams pharmacokinetic enhancer for a renewed use: A retrospective study
- 27 May 2022
- Published by Elsevier in Infectious Diseases Now
- Vol. 52 (5) , 273-279
Probenecid, an old β-lactams pharmacokinetic enhancer for a renewed use: A retrospective study
- Open Access
- 26 January 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 289
Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount for efficacy and absence of toxicity in critically ill patients. Amikacin is a major antibiotic used in nosocomial sepsis, especially for these patients. We aimed to describe amikacin pharmacokinetics on V-A ECMO support and to determine relevant variables to improve its dosing. All critically ill patients requiring empirical antimicrobial therapy, including amikacin for nosocomial sepsis supported or not by V-A ECMO, were included in a prospective population pharmacokinetic study. This population pharmacokinetic analysis was built with a dedicated software, and Monte Carlo simulations were performed to identify doses achieving therapeutic plasma concentrations. Thirty-nine patients were included (control n = 15, V-A ECMO n = 24); 215 plasma assays were performed and used for the modeling process. Patients received 29 (24–33) and 32 (30–35) mg/kg of amikacin in control and ECMO groups, respectively. Data were best described by a two-compartment model with first-order elimination. Inter-individual variabilities were observed on clearance, central compartment volume (V1), and peripherical compartment volume (V2). Three significant covariates explained these variabilities: Kidney Disease Improving Global Outcomes (KDIGO) stage on amikacin clearance, total body weight on V1, and ECMO support on V2. Our simulations showed that the adequate dosage of amikacin was 40 mg/kg in KDIGO stage 0 patients, while 25 mg/kg in KDIGO stage 3 patients was relevant. V-A ECMO support had only a secondary impact on amikacin pharmacokinetics, as compared to acute kidney injury.
- 26 January 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (2) , 289
Open AccessPopulation Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) support leads to complex pharmacokinetic alterations, whereas adequate drug dosing is paramount for efficacy and absence of toxicity in critically ill patients. Amikacin is a major antibiotic used in nosocomial sepsis, especially for these patients. We aimed to describe amikacin pharmacokinetics on V-A ECMO support and to determine relevant variables to improve its dosing. All critically ill patients requiring empirical antimicrobial therapy, including amikacin for nosocomial sepsis supported or not by V-A ECMO, were included in a prospective population pharmacokinetic study. This population pharmacokinetic analysis was built with a dedicated software, and Monte Carlo simulations were performed to identify doses achieving therapeutic plasma concentrations. Thirty-nine patients were included (control n = 15, V-A ECMO n = 24); 215 plasma assays were performed and used for the modeling process. Patients received 29 (24–33) and 32 (30–35) mg/kg of amikacin in control and ECMO groups, respectively. Data were best described by a two-compartment model with first-order elimination. Inter-individual variabilities were observed on clearance, central compartment volume (V1), and peripherical compartment volume (V2). Three significant covariates explained these variabilities: Kidney Disease Improving Global Outcomes (KDIGO) stage on amikacin clearance, total body weight on V1, and ECMO support on V2. Our simulations showed that the adequate dosage of amikacin was 40 mg/kg in KDIGO stage 0 patients, while 25 mg/kg in KDIGO stage 3 patients was relevant. V-A ECMO support had only a secondary impact on amikacin pharmacokinetics, as compared to acute kidney injury.
- 20 November 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (5) , 2274-2285
Impact of renal function on hydroxyurea exposure in sickle‐cell disease patients
Aims: This prospective study aimed to develop a population pharmacokinetics (PK) model of hydroxyurea (HU) in patients with sickle cell disease. This model can be used to determine the impact of glomerular filtration rate (GFR) on HU kinetics.Methods: We included 30 patients. They underwent HU pharmacokinetics analyses of plasma and urine. Six underwent PK analyses in 2 periods with and without angiotensin‐converting enzyme inhibitor. HU was assayed with a validated high‐performance liquid chromatography‐UV method. Noncompartmental PK analysis was conducted and a population PK model built with Monolix. This model was validated externally on another 56 patients. HU PK was simulated as a function of GFR.Results: The HU PK model was constructed as a 2‐compartment model with first‐order absorption and elimination. The quality criteria were good, including for external validation. We found that estimated GFR (eGFR) and body weight affected HU PK, with lower eGFR or body weight associated with a higher HU area under the curve. We recommend the monitoring of HU through eGFR and body weight, which together account for 47% of its variability. Urinary HU fractions and renal clearance were higher in the glomerular hyperfiltration group and lower in the moderate chronic kidney disease group, respectively. No differences in nonrenal HU clearance were observed.Conclusion: Estimated GFR has an impact on the kinetics of hydroxyurea, and HU dose should be adapted accordingly. Angiotensin‐converting enzyme inhibitor seems to have minor effect on HU PK in adults with sickle cell disease.
- 20 November 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (5) , 2274-2285
Impact of renal function on hydroxyurea exposure in sickle‐cell disease patients
Aims: This prospective study aimed to develop a population pharmacokinetics (PK) model of hydroxyurea (HU) in patients with sickle cell disease. This model can be used to determine the impact of glomerular filtration rate (GFR) on HU kinetics.Methods: We included 30 patients. They underwent HU pharmacokinetics analyses of plasma and urine. Six underwent PK analyses in 2 periods with and without angiotensin‐converting enzyme inhibitor. HU was assayed with a validated high‐performance liquid chromatography‐UV method. Noncompartmental PK analysis was conducted and a population PK model built with Monolix. This model was validated externally on another 56 patients. HU PK was simulated as a function of GFR.Results: The HU PK model was constructed as a 2‐compartment model with first‐order absorption and elimination. The quality criteria were good, including for external validation. We found that estimated GFR (eGFR) and body weight affected HU PK, with lower eGFR or body weight associated with a higher HU area under the curve. We recommend the monitoring of HU through eGFR and body weight, which together account for 47% of its variability. Urinary HU fractions and renal clearance were higher in the glomerular hyperfiltration group and lower in the moderate chronic kidney disease group, respectively. No differences in nonrenal HU clearance were observed.Conclusion: Estimated GFR has an impact on the kinetics of hydroxyurea, and HU dose should be adapted accordingly. Angiotensin‐converting enzyme inhibitor seems to have minor effect on HU PK in adults with sickle cell disease.
- 1 August 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 142, 42-48
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC–MS/MS
- 1 August 2017
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 142, 42-48
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC–MS/MS